Should you be able to buy a kidney (and for how much )? | FT #shorts

In the bustling markets of Lagos, where traders haggle over everything from yams to imported electronics, the idea of assigning a price to a human kidney feels both alien and oddly familiar. This week, a fresh Financial Times short video has reignited global debate on whether regulated payments for kidney donors should become reality. Featuring Nobel laureate Alvin Roth, author of the influential book Moral Economics, the clip asks a pointed question: should you be able to buy a kidney—and if so, for how much?

Roth's appearance on the FT platform this past Monday has already generated thousands of views and heated commentary across financial Twitter and African business forums. His core argument is straightforward yet provocative: current systems that rely solely on altruism leave thousands of patients waiting, while generous compensation could dramatically expand the supply of life-saving organs without undermining ethical standards. For emerging economies like Nigeria, where chronic kidney disease rates are climbing due to hypertension, diabetes, and limited dialysis infrastructure, the discussion carries immediate stakes.

Globally, an estimated 1.5 million people receive dialysis or transplants each year, yet demand far outstrips supply. In sub-Saharan Africa, the gap is especially stark. Nigeria alone has fewer than 200 functioning dialysis centers for a population exceeding 220 million. Many patients travel to India or Egypt for transplants, often paying between $20,000 and $50,000 out of pocket in largely unregulated cross-border arrangements. These informal channels sometimes border on trafficking, with vulnerable donors from rural areas receiving as little as $2,000–$5,000 while middlemen pocket the rest.

Roth, whose work on market design earned him the 2012 Nobel Prize in Economics alongside Lloyd Shapley, has long advocated for "repugnant markets" to be examined rather than banned outright. In the FT short released just days ago, he suggests that modest, government-regulated payments—perhaps $50,000 to $100,000 per kidney in high-income settings, could coexist with strong safeguards. These would include lifelong health insurance for donors, independent counseling, and strict limits on who can sell. The goal is not to create a free-for-all commodity market but to design incentives that increase supply while protecting the poor.

From a Lagos trading floor perspective, the economics are compelling. A regulated kidney market could generate foreign exchange earnings if Nigeria positioned itself as a medical tourism hub with transparent rules. Private hospitals in Abuja and Lagos already perform hundreds of transplants annually using living donors; adding compensation could formalize what is partly underground. Economists at the University of Lagos estimate that a well-supervised system might attract 5,000–10,000 additional domestic donors within five years, reducing the $300 million Nigeria spends annually on overseas medical treatment.

Critics rightly warn of exploitation. In emerging markets, where average incomes hover near $2,000 per year, even a $10,000 payment represents life-changing money. Without ironclad protections, the poorest could be pressured by family or debt collectors. India's experience after briefly allowing payments in the 1980s and 1990s showed that middlemen quickly dominated, and many donors later regretted decisions due to health complications and social stigma. Roth acknowledges these risks but argues that banning markets has not eliminated them, it has merely driven them into shadows where oversight is impossible.

Financial markets are already pricing related risks. Shares in global dialysis providers such as Fresenius Medical Care and DaVita have dipped slightly this week on speculation that successful compensation schemes could shrink long-term demand for machines. Conversely, pharmaceutical companies developing anti-rejection drugs stand to gain from higher transplant volumes. In Lagos, local health-tech startups are quietly pitching blockchain-based donor registries to regulators, hoping to capture part of any future legal market.

The debate also touches broader questions of moral economics. Roth's framework distinguishes between repugnant transactions that society rejects on principle and those that can be redesigned to serve the common good. Kidney sales sit squarely in the latter category for him. A modest payment, he contends, is no different from compensating firefighters or compensating surrogate mothers in jurisdictions where that practice is legal. The key is transparency and fairness.

For African policymakers, the timing is urgent. The African Union's health ministers are scheduled to discuss organ donation harmonization in Addis Ababa next month. Nigeria's National Health Insurance Authority has signaled openness to pilot programs that would reimburse living donors for lost wages and medical costs, steps short of outright purchase but moving in Roth's direction. International lenders such as the World Bank could attach conditions or funding to such pilots, creating a laboratory for ethical market design.

Price discovery remains contentious. In the United States, some bioethicists propose $100,000 as a baseline to reflect the lifelong risks donors assume. In lower-cost settings like Nigeria, a tiered structure, perhaps $15,000–$25,000 plus comprehensive lifelong care, might balance incentives with affordability. Private insurers could underwrite these payments, turning kidneys into a new asset class within health-financing portfolios.

Skeptics in Lagos markets note that corruption could derail any system. Procurement scandals already plague public hospitals; adding cash flows for organs would require independent oversight bodies with real-time auditing. Yet the alternative, continued reliance on family donors and overseas travel, perpetuates inequality. Wealthy Nigerians fly to Europe or the Gulf for transplants while the poor die waiting.

Roth's intervention arrives at a moment when health economics is intersecting with capital markets more visibly than ever. Sovereign wealth funds in the Gulf have begun investing in transplant centers; African pension funds could follow if legal frameworks stabilize. The FT short may be only ninety seconds long, but its ripple effects are already visible in boardrooms from Johannesburg to Abuja.

As the conversation evolves this week, one fact is clear: the status quo of pure altruism is failing patients and leaving potential donors unprotected. Whether Nigeria and other emerging markets embrace regulated compensation or continue to look away, the moral and financial costs of inaction keep rising.

This is Sarah Okafor for Global1.news, reporting from Lagos.

Source: Financial Times via YouTube — 2026-05-20T00:00:57+00:00.